You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK – Investment bank BTIG has initiated coverage of Fulgent Genetics with a Buy rating and a $20 price target.
In a research note on Thursday, BTIG analyst Sung Ji Nam wrote that Fulgent has shown growth over the past several years.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.